Fibromyalgia Treatment Market - Databook 2025 to 2034

The global fibromyalgia treatment market size was estimated at USD 2.55 billion in 2024 and is projected to be worth around USD 3.84 billion by 2034, growing at a CAGR of 4.17% from 2025 to 2034.

Highlights of the Fibromyalgia Treatment Market

• North America held the largest share of the fibromyalgia treatment market in 2024.
• Asia Pacific is projected to host the fastest-growing market in the coming years.
• By treatment type, the medications segment held a dominant presence in the fibromyalgia treatment market in 2024.
• By treatment type, the therapies segment is expected to grow at the fastest rate in the market during the forecast period of 2025 to 2034.
• By distribution channel, the retail pharmacies segment enjoyed a prominent position in the fibromyalgia treatment market during 2024.
• By distribution channel, the hospital pharmacies segment is projected to expand rapidly in the market in the coming years.

Industry Valuation and Growth Rate Projection

Fibromyalgia treatment typically involves a combination of exercise or other movement therapies, psychological and behavioral therapy, and medications. Fibromyalgia is a long-term or chronic health condition that causes pain and tenderness throughout our body. It causes musculoskeletal pain and fatigue. Fibromyalgia treatment benefits include behavioral therapy, acupuncture, exercise, and medications that can help to relieve symptoms and improve sleep quality. Emerging health policies, changing clinical practices, application of digital health technologies, and awareness among healthcare professionals are driving the growth of the fibromyalgia treatment market.

• According to a report published in August 2022, a total of 1263 phase IV clinical trials were identified, of which 121 were related to fibromyalgia. Of these, 10 clinical trials met the inclusion criteria for the current study.

Fibromyalgia Treatment: Stats and Figures

• According to a report published in January 2025, the prevalence of fibromyalgia in the United States and other countries is nearly 2% to 3%, with the incidence increasing with age.
• The highest incidence occurs in females between the ages of 20 and 55 and is the leading cause of generalized musculoskeletal pain in women.

How has AI Benefited the Fibromyalgia Treatment Market?

Artificial intelligence (AI) in fibromyalgia is used as a promising approach to enhance diagnostic accuracy, treatment effectiveness, and overall patient outcomes. AI and machine learning technologies have also been employed to identify subgroups of fibromyalgia patients using classification algorithms. AI has the potential to transform chronic pain management by guiding the development of effective treatment strategies that are tailored to individual patient needs. This capability comes from AI’s ability to analyze large and heterogeneous datasets to identify hidden patterns.

Industry Leader Announcements

• Johanna Bendell, M.D., Oncology Chief Development Officer, Pfizer

Johanna Bendell, M.D., Oncology Chief Development Officer, Pfizer, said, “Until recently, patients with metastatic hormone-sensitive prostate cancer faced a poor prognosis, particularly in advanced stages, often due to treatment resistance.”

• Roopal Thakkar, MD, Executive Vice President, research and development, chief scientific officer, AbbVie

Roopam Thakkar, MD, Executive Vice President, research and development, chief scientific officer, AbbVie, said, “EMRELIS, AbbVie’s first internally developed solid tumor medicine and our first solid tumor FDA approval in lung cancer, is a treatment to our commitment to develop cancer therapies that aim to improve the course of treatment for patients facing this challenging disease.”

Geographical Insights

North America held the largest share of the fibromyalgia treatment market in 2024. Rising awareness among patients and healthcare professionals, emerging health policies, increased healthcare expenditure, and insurance coverage for chronic pain management are driving the growth of the market in the North American region.

Asia Pacific is projected to host the fastest-growing market in the coming years. Rising demand for early diagnosis and intervention, rising funding in research and development, demand for personalized medicines, and development of targeted therapies are contributing to the growth of the fibromyalgia treatment market in the Asia Pacific region.

Recent Developments in the Fibromyalgia Treatment Market

• In February 2025, a positive update from an ongoing study evaluating the pharmacokinetics, safety, and tolerability of its new SP-26 ketamine extended-release rods when implanted subcutaneously was launched by a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, Silo Pharma, Inc. The SP-26 implant is a novel, self-administered, non-opioid therapeutic intended for the treatment of chronic pain and fibromyalgia.
• In September 2024, Remedee Labs, a startup based in Paris, France, received European approval for its device-based approach to treating chronic fibromyalgia pain.

Competitive Landscape

• Company Name: Pfizer Inc.
• Year of Incorporation: 1942
• Headquarters: New York, New York, United States

More than 180 countries where it operates. It operates in the biopharmaceutical sector, including development, manufacturing, and commercialization of vaccines and medicines, which helps to improve healthcare around the world.

• Company Name: Teva Pharmaceutical Industries Ltd.
• Year of Incorporation: 1944
• Headquarters: Tel Aviv, Israel

It operates in more than 33 countries. It operates in the healthcare sector, including drug manufacturers, which helps to improve healthcare around the world.